18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study

Coreline N. Burggraaff¹,
Jakoba J. Eertink¹,
Pieternella J. Lugtenburg²,
Otto S. Hoekstra³,
Anne I.J. Arens⁴,
Bart de Keizer⁵,
Martijn W. Heymans⁶,
Bronno van der Holt⁷,
Sanne E. Wiegers¹,
Simone Pieplenbosch¹,
Ronald Boellaard³,
Henrica C.W. de Vet⁶,
Josée M. Zijlstra¹,
on behalf of the HOVON Imaging Working Group and the HOVON Lymphoma Working Group

¹Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;
²Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands;
³Department of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;
⁴Department of Radiology, Nuclear Medicine, and Anatomy, Radboud University Medical Center, Nijmegen, The Netherlands;
⁵Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands;
⁶Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and
⁷Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

For correspondence or reprints, contact Josée M. Zijlstra (j.zijlstra{at}amsterdamumc.nl).

Statistics from Altmetric.com